Study to Evaluate a Subcutaneous Four Months Sustained-release Formulation of Triptorelin in Patients With Prostate Cancer

Summary

To identify the proportion of patients remaining medically castrated (testosterone level \< 50 ng/dL) on Day 240 following two administrations of a 4-month sustained-release (SR) formulation of triptorelin.

Timeline

Start

2006-11

Primary completion

—

Completion

2007-10

Outcome

Outcome not reported

Stopped: “The preliminary data do not support the expected sustainable blood levels of triptorelin for a duration of 4 months in all patients.”

Drugs

Indications